Innovent Biologics, Inc. filed its Monthly Return for the period ended 30 April 2026, confirming incremental equity movements and continued compliance with Hong Kong’s minimum public-float rules.

Authorised Capital Stable • Authorised share capital remained unchanged at 5.00 billion ordinary shares with a par value of USD0.00001, equivalent to total authorised capital of USD50,000.

Issued Shares Edge Higher • Total issued shares (excluding treasury shares) rose by 3.05 million to 1.74 billion, a 0.18% increase versus March’s 1.74 billion. • No treasury shares were held or cancelled during the month.

Drivers of Share Increase • Option exercises under the Pre-IPO Share Incentive Plan (77,500 shares) and the Post-IPO Share Option Scheme (187,908 shares) produced 0.27 million new shares, raising HKD9.27 million in gross proceeds. • A further 2.78 million shares were issued under the now-terminated 2020 Restricted Share Plan, accounting for the bulk of the monthly increase. • Aggregate new issuance from all equity-linked programmes totalled 3.05 million shares.

Outstanding Equity Incentives • Post-month-end, 58.43 million options remain outstanding across three schemes: – Pre-IPO Share Incentive Plan: 8.60 million options outstanding. – Post-IPO Share Option Scheme: 44.27 million. – 2024 Share Scheme: 5.56 million; an additional 128.98 million shares are available for future grants under this scheme. • No warrants or convertible securities were outstanding.

Compliance Position • Innovent Biologics confirmed that public float comfortably exceeds the 25% threshold stipulated by Hong Kong Main Board Rule 13.32B. • All share issuances were duly authorised by the board and executed in accordance with applicable listing rules and regulatory requirements.

The modest equity expansion reflects ongoing execution of employee incentive programmes while maintaining regulatory compliance and capital structure stability.